68
Participants
Start Date
February 19, 2019
Primary Completion Date
May 4, 2022
Study Completion Date
May 4, 2022
Zanubrutinib
Zanubrutinib at a dose of 160 mg orally twice a day (BID)
Auckland City Hospital, Auckland
Concord Repatriation General Hospital, Concord
The Saint George Hospital Kogarah, Kogarah
Canberra Hospital, Garran
Box Hill Hospital, Box Hill
Monash Health, Clayton
Peninsula Private Hospital, Frankston
Princess Alexandra Hospital, Brisbane
Flinders Medical Centre, Bedford PK
University Hospital Vinohrady Hematology Department, Prague
Ao Citta Della Salute E Della Scienza Di Torino Presidio O, Torino
Clinical Research Alliance, Inc, Westbury
Hopital de La Conception Aphm, Marseille
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan
The Charlotte Mecklenburg Hospital Authority, Charlotte
Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux
Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna
Universita Degli Studi Di Modena Azienda Ospedaliere Policlinco, Modena
Chu Hopital Lyon Sud, PierreBenite
Hopital Saint Louis, Paris
Peking University Third Hospital, Beijing
Institute of Hematology and Hospital of Blood Disease, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Henan Cancer Hospital, Zhengzhou
Azienda Ospedaliera S Maria Di Terni, Terni
North Shore Hospital, Takapuna
Severance Hospital Yonsei University Health System, Seoul
Beatson West of Scotland Cancer Centre, Glasgow
The Christie Hospital, Greater Manchester
University College Hospital, London
Royal Marsden Hospital, London
Lead Sponsor
BeiGene
INDUSTRY